Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.177 EUR
−38.53 M EUR
0.00 EUR
263.28 M
About Imugene Ltd
Sector
Industry
CEO
Leslie Chong
Website
Headquarters
Sydney
Founded
1986
ISIN
AU000000IMU9
FIGI
BBG000QBRR16
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Related stocks
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Imugene Ltd stocks are traded under the ticker ILA.
Yes, you can track Imugene Ltd financials in yearly and quarterly reports right on TradingView.
Imugene Ltd is going to release the next earnings report on Mar 4, 2026. Keep track of upcoming events with our Earnings Calendar.
ILA net income for the last half-year is −11.55 M EUR, while the previous report showed −28.89 M EUR of net income which accounts for 60.03% change. Track more Imugene Ltd financial stats to get the full picture.
No, ILA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 29, 2025, the company has 23 employees. See our rating of the largest employees — is Imugene Ltd on this list?
Like other stocks, ILA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Imugene Ltd stock right from TradingView charts — choose your broker and connect to your account.